Navigation Links
Hospital Clinic awarded by CEREBRA Foundation for its excellence in early diagnosis of brain damage
Date:4/3/2008

From a certain age on, some children start to show cognitive or learning difficulties which had not been detected before. Most of these problems, around 80%, have their origins in the prenatal period. This is why an early identification is crucial in order to avoid future neurological problems affecting the normal development of the child. This is one of the main objectives of the multidiscipline research group in Foetal and Perinatal Medicine of the Hospital Clnic de Barcelona- IDIBAPS, directed by Dr. Eduard Gratacs. Thanks to the work of his group, it is possible to act from the very first stages, to perform a postnatal monitoring of the neonate and, hence, to reduce the impact of the brain damage acquired during the foetal life.

Because of this important work, the Catalan hospital was acknowledged yesterday in London by the British foundation CEREBRA, formed by 30 different associations, where a total of 8,000 parents of children with brain injure of several degrees gather together. With this acknowledgement, the Hospital Clnic is accredited as an excellence centre and is awarded with 1.2 million euro to finance a multidiscipline research on premature brain damage for the following six years. These pathologies are anomalies affecting at least 10% of the population.

In an act organised in the Spanish Embassy in London, the medical group has presented all the details of the research work currently under way to the media. Dr. Eduard Gratacs, head of the Unit of Mother and Child Medicine of the Hospital Clnic de Barcelona- IDIBAPS has explained how, by promoting research, a number of these disorders can be detected during foetal life, with the aim to apply strategies of early intervention and making a successful postnatal monitoring or the child. This event had the assistance of Mr. Chris Jones, Director of the British CEREBRA Foundation; Mr. Javier Carvajosa, business manager of the London Spanish Embassy; Dr
'/>"/>

Contact: Marc de Semir
mdesemir@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
Source:Eurekalert  

1

GOOD

Page: 1 2 3

Related medicine news :

1. Childrens Hospital of Pittsburgh of UPMC Involved in Projects To Develop Nations First Heart Assist Devices for Young Children
2. NCQA Awards Quality Plus Distinction to Blue Cross and Blue Shield of Minnesota for Physician and Hospital Quality Measures
3. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
4. IPC The Hospitalist Company Sets 2008 Annual Meeting Date
5. National Union Hospital Healthcare Employees District 1199c Endorses Senator Obama
6. Gregory A. Adams Named Northern California Region President of Kaiser Foundation Health Plan and Hospitals
7. Virginia Hospital Center Reports HCAHPS Scores
8. 19 Hospital Units Receive AACN Beacon Award
9. Verathon(R) Offers Enhanced BladderScan(R) Instrument as Part of Continued Program to Eliminate Unnecessary Catheterizations, Decrease Urinary Tract Infections and Assist in Hospital Infection Control
10. Effectively Influencing the Hospital Marketplace to Win a Place on Formularies
11. Sutter Opens Countys First Non-Hospital-Based Nuclear Imaging Option
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hospital Clinic awarded by CEREBRA Foundation for its excellence in early diagnosis of brain damage
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... the adenoids and tonsils, is performed 500,000 times a ... for children with obstructive sleep apnea. However, the ... functioning, behavior, sleep apnea symptoms, and quality of life ... study led by Susan Redline, MD, MPH, director ... Associate Clinic Director of the Division of Sleep Medicine ...
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution and http://HRA Link: ... Zane Benefits’ website, the Affordable Care Act (known as ... 2010 and impacts many areas of health care and ...
(Date:5/21/2013)... 2013 A new study appearing in ... that stem cells harvested from fat (adipose) are more ... to modulate the body’s immune system. , The ... therapies, as adipose tissue-derived stem cells (AT-SCs) are far ... bone marrow and can be collected from waste material ...
(Date:5/21/2013)... 21, 2013 Octo Consulting Group, ... management consulting solutions to the Federal marketplace, has ... In the newly created role, Denny will ... of the firm’s business development function to include ... functions, and leading strategies to achieve the firm’s ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
... Department of Antiquities of Syria and the University of Chicago ... fought in upper Mesopotamia// in 3500 B.C., leading to the ... that the entire area where the excavation was conducted was ... by the archeologists. Hamoukar is in Syria at the Iraqi ...
... related to Food science and consumer acceptance in Norway ... then do experts to cheese.// ,The food compared ... with expert dairy assessors. The rating was based on ... ,There was difference of opinion in both factions. As ...
... will be spending $60 million to buy 1.8 courses ... //Australian Health Minister Tony Abbott confirmed the order yesterday. ... to pharmaceuticals giant GlaxoSmithKline, but Biota had alleged that ... this allegation. This fresh order makes it the third ...
... has been conducted on a six-year-old Pakistani boy at the ... his birthday on 19 December 2005. //,Anupam Sibal, Medical Director ... in ICU but is responding well to medication. Doctors are ... be normal soon.' , ,He refused to give further ...
... Yoga, Acupuncture, Ayurveda, Chinese movement therapies such as ... just some of the commonly used alternative treatments ... Europe. //Perhaps, this is because it’s strongly perceived ... treatment for cancer with the combination of some ...
... of James Cook University's (JCU) has urged the Health ... the University which will help to produce more doctors ... graduation day.// James Cook University is Australia's premier tropical ... The University is named after the British explorer, Captain ...
Cached Medicine News:Health News:Excavations Reveal Clues Of Early Warfare 2
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... May 21, 2013  Janssen R&D Ireland (Janssen) ... the global Phase 3 PROMISE study demonstrating that ... led to sustained virologic response 12 weeks after ... of treatment-experienced genotype 1 chronic hepatitis C adult ... of liver fibrosis, when administered once daily with ...
Breaking Medicine Technology:Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... Disease Week data highlight effects of AMITIZA in ... ... results indicated that,treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant ... were presented at Digestive Disease Week (DDW) 2008, the,largest annual international ...
... Five Oral Presentations at ASCO Annual Meeting Will Further ... Front-line Multiple Myeloma -, CAMBRIDGE, Mass., May 16 ... new data from VELCADE,clinical studies are scheduled to be ... Annual Meeting in Chicago, Illinois, May 30 -,June 3, ...
Cached Medicine Technology:New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
... system was expressly designed to obtain the ... special source and an equally special power ... particular high energy impulses with constant peak ... 'top-flat shaped') allow storage of enough energy ...
... Derm is a KTP laser, very compact ... nm (frequency doubled Nd:YAG) for dermatologic treatments. ... comfortable color LCD Touch-screen. Maximum power ... 0.3, 0.5, 0.7 and 1.0 mm. SmartLite ...
... Erbium (Er:YAG) laser is the ideal instrument ... Smart 2940 Plus, the majority of surface ... a wide range of scar tissue, with ... most cases with the elimination of anaesthetics, ...
... is the result of DEKA s ... of three different methods capable of ... skin. This treatment is designed to ... through the combined action of a ...
Medicine Products: